KRAS and lung cancer: Additional studies by our group utilizing Kras;p53 (KP) mutant mouse lung tumor models6 demonstrate that epithelial subpopulations of lung cancer cells are responsive to MEK inhibitors, whereas drug-resistant lung cancer cells undergo a ZEB1-dependent epithelial-to-mesenchymal transition (EMT)7,8.